Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

Abstract

EGFR expression increases during the natural history of prostate cancer. Correlation with disease progression and hormone-refractory disease suggests that EGFR-targeted drugs could be of therapeutic relevance in prostate cancer.